Cannabics Pharmaceuticals has concluded a clinical trial that evaluated Cannabics SR 5mg to treat cancer anorexia-cachexia syndrome (CACS) and advanced forms of the disease.
The open-label, single group assignment enrolled a total of 24 subjects.
The trial was conducted at Rambam Medical Center (MC) in Israel. European Society for Medical Oncology (ESMO) has recognised Rambam MC’s Oncology Center as a designated Center of Integrated Oncology and Palliative Care.
Rambam MC division of oncology deputy director Gil Bar-Sela is the principal investigator of the trial, which was launched in 2016.
During the trial, patients were treated with Cannabics SR 5mg daily for three months.
The trial’s primary endpoint was weight gain of ≥10% from baseline. Its secondary endpoints comprised improvement in appetite, nutritional intake, reduction in tumor necrosis factor (TNF) alpha, quality of life (QOL) and others.
According to Cannabics, Rambam MC is currently analysing the official results of the trial and expects to publish the same over the next few months.
Cannabics Pharmaceuticals chief technical officer Eyal Ballan said: “We are awaiting the results and expect them to further elucidate an important aspect of our mission in integrating cannabinoid-based therapies into the world of precision medicine; while at the same time focusing our efforts on bringing scientific data to support developments of cannabinoid-based therapies.”
Headquartered in the US, Cannabics is primarily involved in the development of cannabinoid-based medicine and treatments focused on cancer and its side-effects.
